Perceptive Advisors - Q2 2021 holdings

$15.4 Billion is the total value of Perceptive Advisors's 299 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 36.7% .

 Value Shares↓ Weighting
MRTX BuyMIRATI THERAPEUTICS INC$1,029,236,000
+72.9%
6,371,796
+83.4%
6.68%
-11.2%
BBIO BuyBRIDGEBIO PHARMA INC$945,724,000
+97.9%
15,513,856
+100.0%
6.14%
+1.6%
SWTX BuySPRINGWORKS THERAPEUTICS INC$799,362,000
+124.0%
9,699,824
+100.0%
5.19%
+15.1%
BuyRETROPHIN INCnote 2.500% 9/1$768,844,000
+61.9%
90,000,000
+100.0%
4.99%
-16.8%
IOVA BuyIOVANCE BIOTHERAPEUTICS INC$570,346,000
+108.2%
21,919,544
+153.4%
3.70%
+6.9%
FOLD BuyAMICUS THERAPEUTICS INC$445,780,000
+97.4%
46,242,658
+102.3%
2.90%
+1.4%
BuyCOLLEGIUM PHARMACEUTICAL INCnote 2.625% 2/1$379,446,000
+100.2%
35,000,000
+100.0%
2.46%
+2.8%
HZNP BuyHORIZON THERAPEUTICS PUB L$371,750,000
+97.0%
3,970,004
+93.7%
2.41%
+1.2%
VBIV BuyVBI VACCINES INC CDA$368,784,000
+115.4%
110,084,930
+100.0%
2.40%
+10.6%
LABP BuyLANDOS BIOPHARMA INC$343,494,000
+143.7%
29,739,830
+100.0%
2.23%
+25.1%
NVTA BuyINVITAE CORP$325,076,000
+58.7%
9,637,602
+79.8%
2.11%
-18.5%
BuyNEVRO CORPnote 2.750% 4/0$312,552,000
+131.0%
18,000,000
+100.0%
2.03%
+18.6%
ZYME BuyZYMEWORKS INC$298,722,000
+118.4%
8,611,200
+98.8%
1.94%
+12.1%
GBT BuyGLOBAL BLOOD THERAPEUTICS IN$290,854,000
+41.1%
8,305,378
+64.2%
1.89%
-27.5%
NVRO BuyNEVRO CORP$271,484,000
+139.6%
1,637,520
+101.6%
1.76%
+23.0%
RCKT BuyROCKET PHARMACEUTICALS INC$243,736,000
+91.6%
5,503,206
+91.9%
1.58%
-1.6%
OM BuyOUTSET MED INC$238,658,000
+83.8%
4,775,070
+100.0%
1.55%
-5.6%
CERE BuyCEREVEL THERAPEUTICS HLDNG I$237,912,000
+273.2%
9,286,190
+100.0%
1.54%
+91.7%
ALDX BuyALDEYRA THERAPEUTICS INC$224,422,000
+117.0%
19,807,758
+127.6%
1.46%
+11.5%
UTHR BuyUNITED THERAPEUTICS CORP DEL$221,320,000
+656.1%
1,233,604
+604.9%
1.44%
+288.4%
MGTX BuyMEIRAGTX HLDGS PLC$215,396,000
+130.7%
13,896,554
+100.4%
1.40%
+18.5%
NAUT NewNAUTILUS BIOTECHNOLOGY INC$180,004,00017,822,302
+100.0%
1.17%
CCCC BuyC4 THERAPEUTICS INC$170,928,000
+46.3%
4,517,132
+43.0%
1.11%
-24.8%
OMIC NewSINGULAR GENOMICS SYSTEMS IN$169,434,0006,165,740
+100.0%
1.10%
ALBO BuyALBIREO PHARMA INC$166,060,000
+99.6%
4,720,278
+100.0%
1.08%
+2.6%
RXDX BuyPROMETHEUS BIOSCIENCES INC$162,786,000
+194.1%
6,628,064
+100.0%
1.06%
+51.0%
NBIX BuyNEUROCRINE BIOSCIENCES INC$158,014,000
+72.5%
1,623,664
+72.4%
1.03%
-11.4%
RAPT BuyRAPT THERAPEUTICS INC$157,402,000
+186.2%
4,951,320
+99.9%
1.02%
+46.8%
CRNX BuyCRINETICS PHARMACEUTICALS IN$149,424,000
+189.5%
7,927,034
+116.6%
0.97%
+48.5%
RLAY BuyRELAY THERAPEUTICS INC$147,684,000
+111.7%
4,036,194
+100.0%
0.96%
+8.7%
BEAM BuyBEAM THERAPEUTICS INC$138,398,000
+265.8%
1,075,270
+100.0%
0.90%
+88.1%
ZY NewZYMERGEN INC$130,698,0003,266,664
+100.0%
0.85%
CHRS BuyCOHERUS BIOSCIENCES INC$129,936,000
+89.3%
9,395,224
+100.0%
0.84%
-2.8%
ATNX BuyATHENEX INC$125,040,000
+118.1%
27,064,934
+100.0%
0.81%
+12.0%
ESTA BuyESTABLISHMENT LABS HLDGS INC$122,348,000
+98.2%
1,400,816
+41.9%
0.80%
+1.8%
KDMN BuyKADMON HLDGS INC$121,606,000
+99.0%
31,422,668
+100.0%
0.79%
+2.2%
KRON BuyKRONOS BIO INC$121,094,000
+52.0%
5,056,104
+81.9%
0.79%
-22.0%
QTNT BuyQUOTIENT LTD$117,942,000
+97.8%
32,401,636
+100.0%
0.77%
+1.6%
MGNX BuyMACROGENICS INC$115,394,000
+68.7%
4,296,120
+100.0%
0.75%
-13.4%
MDT NewMEDTRONIC PLC$111,716,000900,000
+100.0%
0.73%
MORF BuyMORPHIC HLDG INC$107,680,000
+81.4%
1,876,280
+100.0%
0.70%
-6.9%
SLDB BuySOLID BIOSCIENCES INC$98,180,000
+32.4%
26,825,104
+100.0%
0.64%
-32.0%
AVIR BuyATEA PHARMACEUTICALS INC$97,056,000
-47.5%
4,518,448
+45.3%
0.63%
-73.0%
NewCOHERUS BIOSCIENCES INCnote 1.500% 4/1$92,106,0009,000,000
+100.0%
0.60%
CMAX NewCAREMAX INC$85,656,0006,640,000
+100.0%
0.56%
DBVT BuyDBV TECHNOLOGIES S Asponsored adr$84,034,000
+104.9%
15,391,010
+100.0%
0.55%
+5.2%
APLS NewAPELLIS PHARMACEUTICALS INC$83,570,0001,322,324
+100.0%
0.54%
VRCA BuyVERRICA PHARMACEUTICALS INC$81,596,000
+49.2%
7,220,824
+100.0%
0.53%
-23.4%
RAIN NewRAIN THERAPEUTICS INC$78,850,0005,074,038
+100.0%
0.51%
TMCI NewTREACE MED CONCEPTS INC$77,268,0002,471,772
+100.0%
0.50%
TARS BuyTARSUS PHARMACEUTICALS INC$75,140,000
+82.7%
2,592,832
+100.0%
0.49%
-6.2%
AXSM NewAXSOME THERAPEUTICS INC$74,734,0001,107,816
+100.0%
0.48%
VERU BuyVERU INC$71,844,000
+49.8%
8,902,684
+100.0%
0.47%
-23.1%
ATHA BuyATHIRA PHARMA INC$70,162,000
+11.3%
6,851,832
+100.0%
0.46%
-42.8%
HCAT BuyHEALTH CATALYST INC$62,846,000
+165.5%
1,132,168
+123.7%
0.41%
+36.5%
XENE BuyXENON PHARMACEUTICALS INC$62,524,000
+578.2%
3,357,946
+552.0%
0.41%
+247.0%
DRNA BuyDICERNA PHARMACEUTICALS INC$59,712,000
+191.9%
1,600,000
+100.0%
0.39%
+49.8%
IMTX BuyIMMATICS N.V$58,050,000
+107.1%
5,000,000
+100.0%
0.38%
+6.5%
EXAS BuyEXACT SCIENCES CORP$58,058,000
+24.6%
467,046
+32.1%
0.38%
-36.0%
BCAB NewBIOATLA INC$58,104,0001,371,038
+100.0%
0.38%
NARI BuyINARI MED INC$57,916,000
-4.2%
620,874
+9.9%
0.38%
-50.8%
ISEE BuyIVERIC BIO INC$57,870,000
+104.2%
9,171,024
+100.0%
0.38%
+5.0%
XLRN NewACCELERON PHARMA INC$56,912,000453,520
+100.0%
0.37%
NUVB BuyNUVATION BIO INC$56,624,000
+95.0%
6,082,008
+100.0%
0.37%
+0.3%
ATEC BuyALPHATEC HLDGS INC$55,158,000
+116.4%
3,600,360
+100.0%
0.36%
+11.2%
TVTX BuyTRAVERE THERAPEUTICS INC$53,854,000
-34.6%
3,691,110
+11.9%
0.35%
-66.4%
GRPH NewGRAPHITE BIO INC$53,784,0001,750,186
+100.0%
0.35%
RNA BuyAVIDITY BIOSCIENCES INC$53,326,000
+122.5%
2,158,056
+96.4%
0.35%
+14.2%
KOD BuyKODIAK SCIENCES INC$53,204,000
+20.6%
572,082
+47.1%
0.35%
-38.0%
ADMA BuyADMA BIOLOGICS INC$53,072,000
+81.8%
33,169,604
+100.0%
0.34%
-6.5%
RGEN NewREPLIGEN CORP$52,900,000265,000
+100.0%
0.34%
ARWR BuyARROWHEAD PHARMACEUTICALS IN$52,200,000
+92.3%
630,282
+54.0%
0.34%
-1.2%
LYRA BuyLYRA THERAPEUTICS INC$51,754,000
+38.6%
6,445,120
+100.0%
0.34%
-28.8%
COGT BuyCOGENT BIOSCIENCES INC$51,722,000
+84.7%
6,377,500
+100.0%
0.34%
-5.1%
PMVP BuyPMV PHARMACEUTICALS INC$51,004,000
+107.7%
1,493,114
+100.0%
0.33%
+6.4%
INBX NewINHIBRX INC$49,926,0001,814,180
+100.0%
0.32%
CLDX NewCELLDEX THERAPEUTICS INC NEW$49,672,0001,485,398
+100.0%
0.32%
COLL BuyCOLLEGIUM PHARMACEUTICAL INC$46,252,000
+99.5%
1,956,554
+100.0%
0.30%
+2.4%
FBRX BuyFORTE BIOSCIENCES INC$46,060,000
+96.2%
1,370,000
+100.0%
0.30%
+0.7%
STOK BuySTOKE THERAPEUTICS INC$45,238,000
+73.3%
1,343,956
+100.0%
0.29%
-10.9%
AGRX BuyAGILE THERAPEUTICS INC$42,348,000
+27.9%
31,839,850
+100.0%
0.28%
-34.4%
VYNE BuyVYNE THERAPEUTICS INC$40,534,000
-12.6%
11,547,908
+70.5%
0.26%
-55.1%
ONCR BuyONCORUS INC$40,396,000
+45.8%
2,927,198
+47.1%
0.26%
-25.1%
CLOV BuyCLOVER HEALTH INVESTMENTS CO$39,960,000
+287.1%
3,000,000
+100.0%
0.26%
+98.5%
VRNA BuyVERONA PHARMA PLCsponsored ads$37,786,000
+56.5%
5,777,778
+100.0%
0.24%
-19.7%
DAWN NewDAY ONE BIOPHARMACEUTICALS I$34,430,0001,512,094
+100.0%
0.22%
ONEM Buy1LIFE HEALTHCARE INC$34,120,000
+68.0%
1,032,088
+98.5%
0.22%
-13.6%
CMIIU BuyCM LIFE SCIENCES II INCunit 02/25/2028$33,626,000
+110.2%
2,500,000
+100.0%
0.22%
+7.9%
TDOC NewTELADOC HEALTH INCcall$33,258,000200,000
+100.0%
0.22%
BuyCATABASIS PHARMACEUTICALS IN$32,438,000
+480.5%
15,374,370
+695.1%
0.21%
+197.2%
NewNANOSTRING TECHNOLOGIES INCnote 2.625% 3/0$32,388,0002,000,000
+100.0%
0.21%
IMCR BuyIMMUNOCORE HLDGS PLCads$31,240,000
+83.5%
800,000
+100.0%
0.20%
-5.6%
NEPT BuyNEPTUNE WELLNESS SOLUTIONS I$30,068,000
+81.6%
25,699,412
+100.0%
0.20%
-6.7%
ACRS BuyACLARIS THERAPEUTICS INC$29,852,000
+82.2%
1,700,000
+161.5%
0.19%
-6.3%
HCAQ BuyHEALTHCOR CATALIO ACQU CORPcl a shrs$29,550,000
+98.6%
3,000,000
+100.0%
0.19%
+2.1%
NBTX BuyNANOBIOTIX SAsponsored ads$29,208,000
+83.2%
2,119,600
+100.0%
0.19%
-5.9%
VRDN NewVIRIDIAN THERAPEUTICS INC$29,062,0001,589,012
+100.0%
0.19%
ADPT BuyADAPTIVE BIOTECHNOLOGIES COR$28,832,000
+103.0%
705,608
+100.0%
0.19%
+3.9%
FUSN BuyFUSION PHARMACEUTICALS INC$28,686,000
+37.2%
3,550,334
+82.1%
0.19%
-29.5%
VTRS BuyVIATRIS INC$28,706,000
+104.6%
2,008,838
+100.0%
0.19%
+5.1%
LPTX BuyLEAP THERAPEUTICS INC$27,802,000
+72.6%
16,952,992
+100.0%
0.18%
-11.3%
HRMY BuyHARMONY BIOSCIENCES HLDGS IN$27,740,000
+169.4%
982,664
+215.3%
0.18%
+38.5%
CMLTU NewCM LIFE SCIENCES III INCunit 04/30/2028$27,376,0002,500,000
+100.0%
0.18%
ACCD BuyACCOLADE INC$26,692,000
+70.2%
491,482
+42.2%
0.17%
-12.6%
CVRX NewCVRX INC$24,640,000880,000
+100.0%
0.16%
BLSA BuyBCLS ACQUISITION CORP$21,060,000
+99.2%
2,000,000
+100.0%
0.14%
+2.2%
CTMX BuyCYTOMX THERAPEUTICS INC$20,774,000
+24.8%
3,281,914
+52.4%
0.14%
-36.0%
RACB BuyRESEARCH ALLIANCE CORP II$20,280,000
+97.9%
2,000,000
+100.0%
0.13%
+1.5%
SMIHU NewSUMMIT HEALTHCRE ACQUISTN COunit 06/03/2026$20,020,0002,000,000
+100.0%
0.13%
DNAY NewCODEX DNA INC$18,700,000850,000
+100.0%
0.12%
CNCE BuyCONCERT PHARMACEUTICALS INC$18,150,000
+69.1%
4,301,282
+100.0%
0.12%
-13.2%
FDMT Buy4D MOLECULAR THERAPEUTICS IN$18,072,000
-6.4%
750,512
+68.7%
0.12%
-52.0%
PRVB SellPROVENTION BIO INC$15,992,000
-46.6%
1,896,962
-33.5%
0.10%
-72.6%
PSTX BuyPOSEIDA THERAPEUTICS INC$15,786,000
+109.8%
1,575,490
+100.0%
0.10%
+8.4%
RACA  THERAPEUTICS ACQUISITION COR$15,405,000
-2.3%
1,500,0000.0%0.10%
-49.7%
ACHL BuyACHILLES THERAPEUTICS PLCsponsored ads$14,790,000
+18.3%
1,510,750
+100.0%
0.10%
-39.2%
SILK SellSILK RD MED INC$14,084,000
-18.2%
294,266
-13.5%
0.09%
-58.3%
BuyDARIOHEALTH CORP$14,006,000
+121.8%
655,738
+100.0%
0.09%
+13.8%
TSHA BuyTAYSHA GENE THERAPIES INC$13,586,000
+42.3%
640,880
+36.2%
0.09%
-27.3%
PRVA NewPRIVIA HEALTH GROUP INC$11,980,000270,000
+100.0%
0.08%
AKYA NewAKOYA BIOSCIENCES INC$11,604,000600,000
+100.0%
0.08%
BCTG BuyBCTG ACQUISITION CORP$11,380,000
+104.7%
1,000,000
+100.0%
0.07%
+5.7%
MREO SellMEREO BIOPHARMA GROUP PLCads$10,754,000
-46.8%
3,392,136
-43.5%
0.07%
-72.7%
CHFWU BuyCONSONANCE HFW ACQUISITION Cunit 99/99/9999$10,400,000
+113.1%
1,000,000
+100.0%
0.07%
+9.7%
PRTA NewPROTHENA CORP PLC$10,282,000200,000
+100.0%
0.07%
LGVU BuyLONGVIEW ACQUISITION CORP IIunit 99/99/9999$10,080,000
+100.8%
1,000,000
+100.0%
0.06%
+3.2%
HSAQ BuyHEALTH SCIENCES ACQ CORP 2$9,180,000
+82.3%
900,000
+100.0%
0.06%
-6.2%
TARA BuyPROTARA THERAPEUTICS INC$8,214,000
+23.8%
843,282
+100.0%
0.05%
-36.9%
MRUS BuyMERUS NV$7,374,000
+101.8%
350,000
+100.0%
0.05%
+4.3%
AMWL BuyAMERICAN WELL CORPcl a$7,296,000
+18.3%
580,000
+63.4%
0.05%
-39.7%
RGNX BuyREGENXBIO INC$6,938,000
+193.6%
178,566
+157.7%
0.04%
+50.0%
CMLF BuyCM LIFE SCIENCES INC$6,360,000
+236.3%
454,000
+257.5%
0.04%
+70.8%
FULC NewFULCRUM THERAPEUTICS INC$6,164,000588,236
+100.0%
0.04%
LSAQ BuyLIFESCI ACQUISITION II CORP$6,000,000
+97.2%
600,000
+100.0%
0.04%
+2.6%
GRTX BuyGALERA THERAPEUTICS INC$5,006,000
+122.9%
509,328
+100.0%
0.03%
+17.9%
FREQ SellFREQUENCY THERAPEUTICS INC$4,426,000
-78.0%
444,444
-79.0%
0.03%
-88.6%
CEREW BuyCEREVEL THERAPEUTICS HLDNG I*w exp 06/09/202$3,828,000
+568.1%
266,132
+100.0%
0.02%
+257.1%
MOTS BuyMOTUS GI HLDGS INC$3,746,000
+81.0%
3,601,084
+100.0%
0.02%
-7.7%
SRRA BuySIERRA ONCOLOGY INC$2,596,000
+126.1%
133,310
+100.0%
0.02%
+13.3%
RACE BuyFERRARI N V$2,556,000
+96.9%
12,400
+100.0%
0.02%
+6.2%
SGTX BuySIGILON THERAPEUTICS INC$2,682,000
-4.0%
250,000
+100.0%
0.02%
-51.4%
EIGR BuyEIGER BIOPHARMACEUTICALS INC$2,384,000
+92.6%
279,780
+100.0%
0.02%
-6.2%
BFLYWS BuyBUTTERFLY NETWORK INC*w exp 02/12/202$2,254,000
+49.8%
466,666
+100.0%
0.02%
-21.1%
SCPEWS BuySC HEALTH CORP*w exp 99/99/999$2,110,000
+123.3%
1,000,000
+100.0%
0.01%
+16.7%
PLXP SellPLX PHARMA INC$1,586,000
-20.9%
114,918
-48.3%
0.01%
-60.0%
TKNO NewALPHA TEKNOVA INC$1,424,00060,000
+100.0%
0.01%
PHVS BuyPHARVARIS NV$1,006,000
+33.2%
54,000
+100.0%
0.01%
-30.0%
TCRR SellTCR2 THERAPEUTICS INC$1,010,000
-85.4%
61,506
-80.4%
0.01%
-92.0%
CMAXW NewCAREMAX INC*w exp 06/08/202$566,000120,000
+100.0%
0.00%
RAPT NewRAPT THERAPEUTICS INCput$166,00090,000
+100.0%
0.00%
DFHT ExitDEERFIELD HEALTHCARE TECH AC$0-20,000
-100.0%
-0.00%
SANA ExitSANA BIOTECHNOLOGY INC$0-10,000
-100.0%
-0.00%
CVM ExitCEL-SCI CORP$0-33,700
-100.0%
-0.01%
VINCW ExitVINCERX PHARMA INC*w exp 12/24/202$0-300,000
-100.0%
-0.02%
TLIS ExitTALIS BIOMEDICAL CORP$0-250,000
-100.0%
-0.04%
VRAY ExitVIEWRAY INC$0-751,748
-100.0%
-0.04%
TXMD ExitTHERAPEUTICSMD INC$0-2,750,000
-100.0%
-0.05%
DFHTU ExitDEERFIELD HEALTHCARE TECH ACunit 07/16/2025$0-300,000
-100.0%
-0.05%
PHR ExitPHREESIA INC$0-100,000
-100.0%
-0.07%
VINC ExitVINCERX PHARMA INC$0-300,000
-100.0%
-0.07%
SNDX ExitSYNDAX PHARMACEUTICALS INC$0-270,000
-100.0%
-0.08%
FGEN ExitFIBROGEN INCput$0-200,000
-100.0%
-0.09%
PCVX ExitVAXCYTE INC$0-850,000
-100.0%
-0.21%
CMPS ExitCOMPASS PATHWAYS PLCsponsored ads$0-797,404
-100.0%
-0.37%
FMTX ExitFORMA THERAPEUTICS HOLDINGS$0-1,250,000
-100.0%
-0.44%
ACAD ExitACADIA PHARMACEUTICALS INC$0-1,410,305
-100.0%
-0.46%
ARNA ExitARENA PHARMACEUTICALS INC$0-575,007
-100.0%
-0.50%
ALLO ExitALLOGENE THERAPEUTICS INC$0-1,143,790
-100.0%
-0.51%
BIIB ExitBIOGEN INCput$0-600,000
-100.0%
-2.12%
BIIB ExitBIOGEN INCcall$0-748,000
-100.0%
-2.65%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-16
  • View 13F-HR/A filed 2021-08-17
About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q2 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D2024-03-20
SC 13G2024-03-14
SC 13G2024-03-11
SC 13G/A2024-03-06
SC 13D/A2024-03-01
SC 13G2024-03-01
SC 13D/A2024-02-29
13F-HR/A2024-02-26
SC 13G/A2024-02-23
42024-02-21

View Perceptive Advisors's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been amended

Export Perceptive Advisors's holdings